Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model

被引：0
|
作者：
Michael Willis
Andreas Nilsson
Klas Kellerborg
Philip Ball
Rupert Roe
Shana Traina
Rebecca Beale
Isabelle Newell
机构：
[1] The Swedish Institute for Health Economics,
[2] Mundibiopharma Limited,undefined
[3] Napp Pharmaceuticals Limited,undefined
[4] Janssen Global Services,undefined
[5] LLC,undefined
[6] Costello Medical Consulting Limited,undefined
来源：
Diabetes Therapy | 2021年 / 12卷
关键词：
Albuminuria; Canagliflozin; Chronic kidney disease (CKD); Cost-effectiveness; CREDENCE; Diabetes; Diabetic kidney disease (DKD); Diabetic nephropathy; Dialysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：313 / 328
页数：15
相关论文
共 50 条
  • [1] Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
    Willis, Michael
    Nilsson, Andreas
    Kellerborg, Klas
    Ball, Philip
    Roe, Rupert
    Traina, Shana
    Beale, Rebecca
    Newell, Isabelle
    DIABETES THERAPY, 2021, 12 (01) : 313 - 328
  • [2] USE OF A NEW DISCRETE EVENT SIMULATION MODEL TO PREDICT THE COST EFFECTIVENESS OF CANAGLIFLOZIN ADDED TO STANDARD OF CARE FOR TREATING DIABETIC KIDNEY DISEASE (DKD) IN PATIENTS WITH TYPE 2 DIABETES IN ENGLAND
    Ball, P.
    Willis, M.
    Nilsson, A.
    Traina, S.
    Roe, R.
    Kellerborg, K.
    VALUE IN HEALTH, 2020, 23 : S510 - S510
  • [3] The association between thyroid dysfunction (TD) and diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM)
    Zheng, Mao
    Wang, Dong
    Chen, Li
    Chen, Mei-Nan
    Wang, Wei
    Ye, Shan-Dong
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2019, 73 (12)
  • [4] Diabetic Kidney Disease (DKD) in UK Patients With Type 2 Diabetes (T2D)
    Ruzafa, Javier Cid
    Paczkowski, Rosirene
    Boye, Kristina S.
    Di Tanna, Gian Luca
    Sheetz, Matthew J.
    Donaldson, Robert
    Breyer, Matthew D.
    Neasham, David
    Voelker, James R.
    DIABETES, 2013, 62 : A397 - A397
  • [5] THE EFFECT OF TREATMENT INTENSIFICATION ASSUMPTIONS ON ESTIMATES OF COST-EFFECTIVENESS IN TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    Johansen, P.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [6] SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF DAPAGLIFLOZIN TREATING PATIENTS OF TYPE 2 DIABETES MELLITUS (T2DM)
    Hu, C.
    Zhang, C.
    Wang, B.
    Xu, L.
    VALUE IN HEALTH, 2018, 21 : S39 - S39
  • [7] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [8] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [9] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [10] COST-EFFECTIVENESS OF CANAGLIFLOZIN TREATMENT IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE
    Wu, B.
    VALUE IN HEALTH, 2019, 22 : S584 - S584
12345